TRENTON, N.J. — A less-expensive version of the world’s top-selling insulin, Sanofi’s Lantus, could go on sale in the U.S. late next year. The French drugmaker said Monday it settled a lawsuit over ...

The FDA has approved Apidra SoloSTAR (insulin glulisine[rDNA origin] injection, from sanofi-aventis), a prefilled disposable pencontaining Apidra. Apidra SoloSTAR makes administration of insulin ...

Basaglar (insulin glargine) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to: improve blood sugar levels in adults ...

FILE PHOTO: The logo of Sanofi is pictured during the Viva Tech start-up and technology summit in Paris, France, May 25, 2018. REUTERS/Charles Platiau (Reuters) - U.S. generics drugmaker Mylan said on ...

The FINANCIAL — Sanofi announced on September 28 that it has reached a settlement agreement with Eli Lilly and Company, which addresses patents on Sanofi’s Lantus SoloSTAR (insulin glargine). The ...

NEW YORK Sanofi-aventis’ SoloSTAR insulin pen has some serious competition. Two independent studies in Germany and Japan have found that Novo Nordisk’s FlexPen was more accurate in delivering insulin ...

The follow-on or copycat insulin glargine product Basaglar (Lilly) is similar to brand-name Lantus (Sanofi) in terms of efficacy and safety for the treatment of type 2 diabetes, but Basaglar cost less ...

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY. Similar to Lilly, Sanofi also said it is ...

After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

(Reuters) - U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus. Sanofi is ...